• No results found

University of Groningen The gut microbiota and inflammatory bowel disease Collij, Valerie

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen The gut microbiota and inflammatory bowel disease Collij, Valerie"

Copied!
8
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

The gut microbiota and inflammatory bowel disease

Collij, Valerie

DOI:

10.33612/diss.150928851

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2021

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Collij, V. (2021). The gut microbiota and inflammatory bowel disease: From exploration to clinical translation. University of Groningen. https://doi.org/10.33612/diss.150928851

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

The gut microbiota and

inflammatory bowel disease

From exploration to clinical translation

(3)

Printing this thesis was financially supported by the University of Groningen, the Graduate School of Medical Sciences of the University Medical Center Groningen, Norgine, Takeda, Dr. Falk Pharma Benelux B.V. and Tramedico.

Printed by Ipskamp Printing, Enschede, the Netherlands Cover design by Robert Faber

Design and lay-out by Douwe Oppewal, www.oppewal.nl

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the author, or when appropriate, of the publishers of the publications included in this thesis.

(4)

The gut microbiota and

inflammatory bowel disease

From exploration to clinical translation

Proefschrift

ter verkrijging van de graad van doctor aan de

Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. C. Wijmenga

en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

woensdag 3 februari 2021 om 14.30 uur

door

Valerie Collij

geboren op 2 april 1993

te Groningen

(5)

Promotores Prof. dr. R.K. Weersma Prof. dr. J. Yang-Fu Copromotor Dr. A. Vich Vila Beoordelingscommissie Prof. dr. H.J. Verkade Prof. dr. D. Jonkers Prof. dr. M. Kleerebezem

(6)

Paranimfen

Dr. M. Kloosterman Dr. F. Imhann

(7)
(8)

Table of contents

Chapter 1 Introduction 9

Part I - Exploring the role of the gut microbiota in IBD

Chapter 2 Gut microbiota composition and functional changes in 23 inflammatory bowel disease and irritable bowel syndrome

Science Translational Medicine 2018;10:eaap8914

Chapter 3 Gut microbial co-abundance networks show specificity in 45 inflammatory bowel disease and obesity

Nature Communications 2020;11:4018

Chapter 4 The composition and metabolic potential of the human small 73 intestinal microbiota and its possible implications in IBD

Submitted

Chapter 5 SLC39A8 missense variant is associated with Crohn’s disease 93 but does not have a major impact on gut microbiome composition in healthy subjects

Plos One 2019;14:e0211328

Part II - Clinical translation – Drugs and (meta)genomics

Chapter 6 Drug repositioning in inflammatory bowel disease based 111 on genetic information

Inflammatory bowel disease 2016;22:2562-2570

Chapter 7 Gut microbiome and proteomic changes as biomarker of 129 response to vedolizumab treatment in patients with

inflammatory bowel disease Submitted

Chapter 8 Impact of commonly used drugs on the composition 151 and metabolic function of the gut microbiota

Nature Communications 2020;11:362

Chapter 9 Gut microbiota in inflammatory bowel diseases: 171 Moving from basic science to clinical applications

Human Genetics 2020: doi: 10.1007/s00439-020-02218-3

Chapter 10 Discussion 183

Appendices Nederlandse samenvatting 206

English summary 209

Curriculum vitae 211

List of publications 212

Referenties

GERELATEERDE DOCUMENTEN

To disentangle these complex relations, the combination of longitudinal studies (from pre-treatment to wash-out period) with in- vitro experiments can be a good approach.

entire ecosystem with interacting microbes, it is pivotal to further explore the other members of the gut microbiota. From a clinical perspective, the potential role of viruses

study called IBD tracker that is following 50 patients with IBD and frequently collecting faecal samples, with the goal of shedding more light on gut microbial changes, especially

Vich Vila A*, Imhann F*, Collij V*, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Jiang X, Tigchelaar EF, Dekens J, Peters V, Voskuil MD, Visschedijk MC, van

An increase of microbial richness is a potential biomarker for defining response to vedolizumab treatment in patients with inflammatory bowel disease (This thesis) 8.

We performed RNA sequencing analyses of single cells (scRNAseq) from the intestinal mucosa and peripheral blood of patients with CD to identify cells that express CD risk genes

Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease using data from the Exome Wide Association Study

We next assessed the clinical efficacy of pharmacogenetic testing for three applications: A) to predict thiopurine toxicity (i.e. myelosuppression and pancreatitis) prior to